1. Show article details.

    Keryx Biopharmaceuticals to Host Conference Call on Fourth Quarter and Year End 2015 Financial Results on Thursday, February 25, 2016

    GlobeNewswire – 8:00 AM ET 02/11/2016

    Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative medicines to market for people with renal disease, today announced that it will host a conference call and webcast on Thursday, February 25, 2016 at 8:00 a.m. ET to discuss its fourth quarter and year end 2015 financial results and provide a review of the Auryxia™ launch.

  2. Show article details.

    Covered Call Alerts For Disney, Avon Products, General Electric, Keryx Biopharmaceuticals and JC Penney Released By InvestorsObserver

    PR Newswire – 9:31 AM ET 02/01/2016

    CHICAGO, Feb. 1, 2016 InvestorsObserver issues critical PriceWatch Alerts for DIS, AVP, GE, KERX and JCP. To see the high-return covered-call trades uncovered by InvestorsObserver's analysts, read the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.

  3. Show article details.

    Klarman's Baupost fund posts 2015 losses due to energy firms

    Reuters – 6:41 PM ET 01/29/2016

    Billionaire investor Seth Klarman, whose Baupost Group hedge fund ranks among the world's largest and most admired, told clients he lost money last year, in part because bets on energy companies failed to pay off. In a client letter seen by Reuters, Klarman wrote the fund posted a "a mid-single-digit decline" for 2015 and said he would give investors more details in early February.

  4. Show article details.

    Covered Call Alerts For NVIDIA, Keryx Biopharmaceuticals, Fitbit, Gilead Sciences and Chipotle Mexican Grill Released By InvestorsObserver

    PR Newswire – 9:31 AM ET 01/20/2016

    CHICAGO, Jan. 20, 2016 InvestorsObserver issues critical PriceWatch Alerts for NVDA, KERX, FIT, GILD and CMG. To see the high-return covered-call trades uncovered by InvestorsObserver's analysts, read the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.

  5. Show article details.

    Covered Call Alerts For Kinder Morgan, Qorvo, CSX, Goldcorp and Keryx Biopharmaceuticals Released By InvestorsObserver

    PR Newswire – 9:31 AM ET 01/08/2016

    CHICAGO, Jan. 8, 2016  InvestorsObserver issues critical PriceWatch Alerts for KMI, QRVO, CSX, GG and KERX. To see the high-return covered-call trades uncovered by InvestorsObserver's analysts, read the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.

  6. Show article details.

    Covered Call Alerts For Fitbit, Keryx Biopharmaceuticals, SolarEdge Technologies, Chipotle Mexican Grill and Exelixis Released By InvestorsObserver

    PR Newswire – 9:31 AM ET 12/28/2015

    CHICAGO, Dec. 28, 2015  InvestorsObserver issues critical PriceWatch Alerts for FIT, KERX, SEDG, CMG and EXEL. To see the high-return covered-call trades uncovered by InvestorsObserver's analysts, read the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.

  7. Show article details.

    Keryx Biopharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11

    GlobeNewswire – 4:05 PM ET 12/22/2015

    Keryx Biopharmaceuticals, Inc (KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, today announced it will present at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 11, 2016 at 9:30 a.m. PST.

  8. Show article details.

    Keryx Announces Appointment of John P. Butler to its Board of Directors

    GlobeNewswire – 8:00 AM ET 12/10/2015

    Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, today announced that John P. Butler has been appointed as a new independent director to its board of directors pursuant to the company’s financing transaction with The Baupost Group, L.L.C., effective immediately.

  9. Show article details.

    Covered Call Alerts For Opko Health, Intrexon, CyberArk Software, Keryx Biopharmaceuticals and Twitter Released By InvestorsObserver

    PR Newswire – 9:31 AM ET 12/09/2015

    CHICAGO, Dec. 9, 2015  InvestorsObserver issues critical PriceWatch Alerts for OPK, XON, CYBR, KERX and TWTR. To see the high-return covered-call trades uncovered by InvestorsObserver's analysts, read the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.

  10. Show article details.

    Keryx Biopharmaceuticals Announces Webcast of Presentation at Oppenheimer's 26th Annual Healthcare Conference

    GlobeNewswire – 9:05 AM ET 12/01/2015

    Keryx Biopharmaceuticals, Inc (KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, today announced it will present at the Oppenheimer & Co., Inc. 26th Annual Healthcare Conference in New York City on December 8, 2015 at 9:45 a.m. EST.

  11. Show article details.

    Covered Call Alerts For Opko Health, Kandi Technologies, Keryx Biopharmaceuticals, Exxon Mobil and El Pollo Loco Released By InvestorsObserver

    PR Newswire – 9:31 AM ET 11/27/2015

    CHICAGO, Nov. 27, 2015 InvestorsObserver issues critical PriceWatch Alerts for OPK, KNDI, KERX, XOM and LOCO. To see the high-return covered-call trades uncovered by InvestorsObserver's analysts, read the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.

  12. Show article details.

    Covered Call Alerts For Chesapeake Energy, Mylan, Keryx Biopharmaceuticals, Yelp and Corning Inc. Released By InvestorsObserver

    PR Newswire – 9:31 AM ET 11/16/2015

    CHICAGO, Nov. 16, 2015  InvestorsObserver issues critical PriceWatch Alerts for CHK, MYL, KERX, YELP and GLW. To see the high-return covered-call trades uncovered by InvestorsObserver's analysts, read the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.

  13. Show article details.

    Keryx Biopharmaceuticals Announces Participation at Two Upcoming Investor Conferences

    GlobeNewswire – 4:05 PM ET 11/03/2015

    Keryx Biopharmaceuticals, Inc (KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, today announced that corporate presentations would be delivered at the following upcoming investor conferences.

  14. Show article details.

    Keryx Biopharmaceuticals Announces Third Quarter 2015 Financial Results

    GlobeNewswire – 7:00 AM ET 10/29/2015

    – Growth in third quarter Auryxia™ product sales driven by increased breadth and depth of prescribers – – Keryx well positioned with strengthened cash position to support Auryxia commercialization and expansion opportunities – BOSTON, Oct. 29, 2015 -- Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, tod...

  15. Show article details.

    Keryx Biopharmaceuticals to Host Conference Call of Third Quarter 2015 Financial Results on Thursday, October 29, 2015

    GlobeNewswire – 9:05 AM ET 10/21/2015

    Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, today announced that it will host a conference call and webcast on Thursday, October 29, 2015 at 8:00 a.m. ET to discuss its third quarter 2015 financial results and provide a review of the Auryxia™ launch.

  16. Show article details.

    Keryx Biopharmaceuticals Announces $125 Million Private Placement of Convertible Senior Notes With The Baupost Group, L.L.C.

    GlobeNewswire – 7:00 AM ET 10/15/2015

    Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, today announced that it has entered into an agreement to raise $125 million through the private placement of Convertible Senior Notes, due 2020, with funds managed by The Baupost Group, L.L.C. With the additional capital, Keryx has a pro-forma cash positi...

  17. Show article details.

    Keryx Receives European Approval for Fexeric(R) (ferric citrate coordination complex) for the Treatment of Hyperphosphatemia in Adults With Chronic Kidney Disease

    GlobeNewswire – 7:00 AM ET 09/24/2015

    Keryx Biopharmaceuticals, Inc. (KERX) today announced that the European Commission has approved Fexeric® for the control of elevated serum phosphorus levels, or hyperphosphatemia, in adults with chronic kidney disease, including both dialysis and pre-dialysis patients.

  18. Show article details.

    Keryx Biopharmaceuticals Announces Participation at Upcoming Investor Conferences

    GlobeNewswire – 8:30 AM ET 09/09/2015

    Keryx Biopharmaceuticals, Inc (KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients with renal disease, today announced that corporate presentations would be delivered at the following upcoming investor conferences.

Page:

Today's and Upcoming Events

  • Feb
    25

    KERX to announce Q4 earnings Before Market (Confirmed)

  • Feb
    25

    KERX Earnings Conference Call at 8:00 AM Listen

Past Events (last 90 days)

No events in the past 90 days

Data provided by Wall Street Horizon, Inc. © 2016

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.